Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “PSEUDOMONAS INFECTIONS”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 757 records · Page 42Linked to original sources
PubMed1982

[Clinical study of cefsulodin on Pseudomonas aeruginosa infections in otorhinolaryngology].

The clinical effect of cefsulodin (CFS) on Pseudomonas aeruginosa infections in otorhinolaryngology was studied in 10 patients. The overall clinical effectiveness was 80% (excellent 2, good 6, poor 2). Eradication rates of P. aeruginosa was 60%. No side effect and positive skin test were found in any cases. Examination of laboratory data before and after the administration revealed no abnormal findings in every cases.

Adult↗
PubMed1988

Monoclonal antibodies provide protection against ocular Pseudomonas aeruginosa infection.

A panel of well characterized monoclonal antibodies (MAbs) directed against outer membrane proteins H2, or F (porin) of Pseudomonas aeruginosa were examined to determine whether they exhibited any protective effect against subsequent ocular challenge with the bacteria topically applied to the scarified corneal surface. Mice were observed macroscopically following bacterial challenge and the degree of ocular disease graded on a scale of 0 to 4 (0, normal, fully protected cornea; 4, corneal perforation or phthisis, not protected). Mice treated intravenously with either MAb MA1-6 (anti-H2) or MA2-10 (anti-F), or a combination of these two MAbs and MAb MA4-4 (anti-F), two hours before corneal challenge with the viable bacteria, exhibited significantly less corneal disease than mice either not treated with the MAbs, treated with MA4-4 alone or treated with MAb MA1-3 (anti-I). The latter MAb is directed against an outer membrane epitope that is not surface exposed. Light and transmission electron microscopic histopathology also was employed and provided confirmatory evidence to support the macroscopic analyses.

Animals↗
PubMed1975

Epidemiology of Pseudomonas aeruginosa infections investigated by pyocin typing.

All strains of Pseudomonas aeruginosa isolated in a large Canadian hospital over a 3-year period were typed by their pyocin production. Smaller collections of P. aeruginosa from other hospitals were also typed. Almost 3000 strains were examined. The typing method did not require use of complex reagents and was successful in subdividing P. aeruginosa into numerous types. No single type was restricted to infections of one particular kind. Infections of all kinds were associated with a wide variety of pyocin types. Extensive crossinfection with one particular pyocin type was observed only in urinary infection of patients with urologic disorders. The four pyocin types that were most frequent in our entire series have been reported as the commonest types causing infections in many other parts of the world.

Cross Infection↗
PubMed1990

Protective effect of baker's yeast mannan against Listeria monocytogenes and Pseudomonas aeruginosa infection in mice.

The neutral mannan (WNM) and the acidic mannan (WAM025) fractions from baker's yeast (Saccharomyces cerevisiae) were found to manifest significant protective effects against intraperitoneal and intravenous infections of Listeria monocytogenes and Pseudomonas aeruginosa in mice. A remarkable decrease in the number of microbial cells in spleen and liver was observed in mice inoculated with these microorganisms after administration of either mannan fraction. In order to clarify the mechanism of the protective effects, we investigated in vitro the bactericidal activity and lysosomal enzyme activities such as myeloperoxidase, acid phosphatase, and neutral protease, in Kupffer cells (KCs) from mice pretreated with either mannan fraction. KCs from mice administered with these mannan fractions showed an enhanced killing effect on these bacteria in vitro, and neutral protease activity was considered to be one of the important factors in the killing effect on both L. monocytogenes and P. aeruginosa.

Animals↗
PubMed2005

Evaluating ciprofloxacin dosing for Pseudomonas aeruginosa infection by using clinical outcome-based Monte Carlo simulations.

Pseudomonas aeruginosa causes serious infections whose outcome is highly dependent on antimicrobial therapy. The goal of this study was to predict the relative efficacies of three ciprofloxacin dosing regimens for P. aeruginosa infection using clinical outcome-based Monte Carlo simulations (MCS) with "real patient" demographics, pharmacokinetics, MICs, and pharmacodynamics (PDs). Each cohort consisted of 1,000 simulated study subjects. Three ciprofloxacin dosing regimens were studied, including (i) the recommended standard dose of 400 mg given intravenously (i.v.) every 12 h (q12h), (ii) the recommended high dose of 400 mg i.v. q8h, and (iii) a novel, PD-targeted regimen to attain a fAUC/MIC value of >86. Probability of target attainment (PTA) and probability of cure (POC) were determined for each regimen. POC with the standard dose was at least 0.90 if pathogen MICs were < or =0.25 microg/ml but only 0.59 or 0.27 if MICs were 0.5 or 1 microg/ml, respectively. Predicted cure rates in these MIC categories were significantly higher at 0.72 and 0.40 with the high dose and 0.91 and 0.72 with the PD-targeted regimen(P < 0.0001). Analyses based on the local susceptibility profile produced PTA and POC estimates of 0.44 and 0.74 with the standard ciprofloxacin dose, 0.58 and 0.81 with the high dose, and 0.84 and 0.93 with the PD-targeted regimen, respectively. In conclusion, as demonstrated by clinical outcome-based MCSs, the highest recommended ciprofloxacin dose of 400 mg i.v. q8h should be used in the treatment of P. aeruginosa infection to improve PD target attainment and clinical cure. However, even this appears ineffective if pathogen MICs are 1 mug/ml, warranting the consideration of a lower MIC breakpoint, < or =0.5 microg/ml.

Anti-Infective Agents↗
PubMed2003

Bacteriophage control of Pseudomonas plecoglossicida infection in ayu Plecoglossus altivelis.

Two previously isolated phages were used to examine the therapeutic effects against Pseudomonas plecoglossicida infection in ayu Plecoglossus altivelis. Phage PPp-W4 (Podoviridae) inhibited the in vitro growth of P. plecoglossicida more effectively than Phage PPpW-3 (Myoviridae), and a mixture (PPpW-3/W-4) of the 2 phages exhibited the highest inhibitory activity. In phage therapy experiments, ayu were fed P. plecoglossicida-impregnated feed (10(7) CFU fish(-1)) and then fed phage-impregnated feed (10(7) PFU fish(-1)). Mortalities of fish receiving PPpW-3, PPpW-4, PPpW-3/W-4, and a control fish receiving no phages were 53.3, 40.0, 20.0 and 93.3%, respectively. Phage (PPpW-3/W-4)-receiving fish also showed high protection against water-borne infection with P. plecoglossicida. In a field trial, when phage (PPpW-3/W-4)-impregnated feed was administered to ayu in a pond where the disease occurred naturally, daily mortality of fish decreased at a constant level (5% d(-1)) to one-third after a 2 wk period. The causal relationship of phages in this phenomenon was verified by the long-lasting appearance of administered phages in the kidneys of the fish, and a disappearance of P. plecoglossicida from apparently healthy fish. Neither phage-resistant organisms nor phage-neutralizing antibodies were detected in diseased fish or apparently healthy fish, respectively. These results indicate the potential for phage control of the disease.

Administration, Oral↗
PubMed1988

[Routes of the transmission of Pseudomonas aeruginosa infection in resuscitation and intensive therapy departments].

To find out if the transfer of P. aeruginosa infection by droplet route is possible in resuscitation and intensive care units, the bacteriological study of air samples taken in different rooms of resuscitation units (altogether 234 air samples) was carried out with the subsequent identification and typing of isolated P. aeruginosa strains. In most cases (70.5%) the microbial contamination of the air in the main rooms of resuscitation units was found not to exceed 500 microbial cells per cu. m, and no P. aeruginosa strains were isolated. The identification and typing of six P. aeruginosa strains isolated from the air of an isolation ward for patients with infectious complications made it possible to find out intraspecific differences of these microorganisms, as all of them belonged to strains of different sero- and pyocinotypes. Thus, the results of these investigations indicate that the droplet route of the transfer of P. aeruginosa hospital infection is not characteristic of resuscitation and intensive care units, as no P. aeruginosa strains are isolated from the main rooms of such units; likewise, no circulation of this microorganism was observed in the air of an isolation ward for patients with infectious complications.

Air Microbiology↗
PubMed1976

[Protective effect of schizophyllan on Pseudomonas aeruginosa infection of mouse (author's transl)].

Effects of schizophyllan (SPG) and several antibiotics in combination against experimental Pseudomonas aeruginosa infection were examined. (1) Whereas the increase in protective effect of SPG was not observed in combination with carbenicillin or sulbenicillin, remarkable effects could be recognized in combination with dibekacin or gentamicin (GM). The combined therapy with SPG and GM proved to be most excellent. (2) The time course for changes of viable number of Ps. aeruginosa in various organs of mice revealed that the multiplication of the infected bacteria was more markedly inhibited in mice treated with SPG and GM in combination than those treated with each alone. (3) The increase in bactericidal activity of the peritoneal exudate cells was more remarkably demonstrated in the combined treatment with SPG and GM than with each alone, showing the rapid clearance of bacteria from the peritoneal cavity in the former. (4) The microscopic estimation demonstrated that the increase in both phagocytic index and intracellular digestion of bacteria by cultivated macrophages was larger in combination of SPG and GM than each alone. (5) The measurement of viable number of bacteria in cultivated macrophages by the plate-count method also showed that the ingestion and bactericidal activity within the cells were much higher in combined treatment with SPG and GM than each alone.

Animals↗
PubMed1988

Ciprofloxacin therapy of respiratory tract infection with Pseudomonas aeruginosa.

Forty-two patients with respiratory tract infection caused by Pseudomonas aeruginosa were treated with 500 mg ciprofloxacin administered orally twice daily. Pseudomonas aeruginosa was eradicated in 22 patients but recurred in eight patients. Clinical improvement or resolution was noted in 37 patients (88%). Eradication and cure rates were highest in patients without permanent risk factors, and in patients with hospital-acquired infection. New colonization during treatment was noted in 14 patients (33%), but no superinfection occurred. In persisting strains of Pseudomonas aeruginosa the in vitro sensitivity to ciprofloxacin decreased significantly during therapy.

Adolescent↗
PubMed1983

Effect of experimental Pseudomonas aeruginosa infection on the activity of mouse phagocytes.

It has been stated that experimental infection with 0.01 LD50 Pseudomonas aeruginosa 74 decreases the phagocytic activity of mouse neutrophiles and peritoneal macrophages in relation to latex particles. In the course of infection suppression of phagocytic activity of peritoneal macrophages was delayed for two days as compared with that of neutrophiles. During the dying out of infection phagocytic activity of neutrophils and macrophages returned to the control values. Possible mechanisms of these events were discussed.

Animals↗
PubMed1997

[Cystic fibrosis and chronic Pseudomonas aeruginosa infection. Possibilities for immunologic prophylaxis and therapy].

Cystic fibrosis is an autosomal recessive disease, characterised by chronic pulmonary infections, pancreatic insufficiency and increased electrolyte content of sweat. Cystic fibrosis is diagnosed in one out of 4761 children below the age of 15 years. Pulmonary infection was previously caused by Staphylococcus aureus, but after the introduction of penicillin, the mortality was reduced from 61% to 20% within the first five years of life. Today chronic pulmonary infection is primarily caused by Pseudomonas aeruginosa. P. aeruginosa infection produces an immunologically conditioned destruction of the pulmonary tissue, leading to fatal bronchiectasis. P. aeruginosa develops resistance against most antibiotics and chemotherapeutic agents except colistin. Immunological aspects concerning active and passive immunisation are discussed in the article. Until today no useable vaccine has been found, but several candidates are subjects of research.

Adolescent↗